ST-11: A New Brain-Penetrant Microtubule-Destabilizing Agent with Therapeutic Potential for Glioblastoma Multiforme

Area of Science:

• Oncology
• Pharmacology
• Cancer Biology

Background:

• Glioblastoma multiforme (GBM) is an aggressive brain cancer with poor patient survival.
• Current treatments are limited by the blood-brain barrier (BBB) impermeability to many drugs.
• Microtubule (MT)-targeting agents show efficacy in cancers but lack brain penetration for GBM treatment.

Purpose of the Study:

• To discover and characterize a novel, brain-penetrant microtubule-targeting agent for glioblastoma multiforme.
• To evaluate the efficacy and safety of the novel compound ST-11 in preclinical models of GBM.

Main Methods:

• In vitro assessment of ST-11's effect on microtubule assembly and cell cycle progression.
• In vivo evaluation of ST-11's blood-brain barrier penetration in a mouse model.
• Assessment of ST-11's anti-tumor activity and toxicity in an orthotopic mouse model of glioblastoma.

Main Results:

• ST-11 directly inhibits microtubule assembly, causing prometaphase arrest and apoptosis in glioblastoma cells.
• ST-11 demonstrates significant blood-brain barrier penetration, unlike existing antitubulin agents.
• In vivo, ST-11 reduced glioblastoma tumor volume by activating caspase-3, with no observed toxicity.

Conclusions:

• ST-11 is a novel alkylindole compound with potent anti-glioblastoma activity.
• ST-11 represents a new class of brain-penetrant antitubulin agents effective against glioblastoma.
• ST-11 shows therapeutic potential for treating glioblastoma multiforme due to its BBB permeability and efficacy.